STOCKHOLM, Nov. 3, 2021 /PRNewswire/ --
Third quarter
- Revenue amounted to €335.0m (€262.5m), an increase of 27.6%
with an organic growth of 23.9%.
- Operating profit (EBIT) was €30.0m (€27.3m), representing an
operating margin of 9.0% (10.4%).
- Net profit amounted to €18.4m (€19.5m), which represents a net
profit margin of 5.5% (7.5%).
- EBITDA was €58.0m (€50.1m), an increase by 15.7%. EBITDA margin
was 17.3% (19.1%).
- EBITDAaL amounted to €42.8m (€38.1m), corresponding to an
EBITDAaL margin of 12.8% (14.5%).
- Net cash flow from operating activities was €67.0m
(€41.2m).
- Basic/diluted earnings per share were €0.123 (€0.108).
Nine months
- Revenue amounted to €1,001.1m (€700.1m), an increase of 43.0%
with an organic growth of 44.1%.
- Operating profit (EBIT) was €117.8m (€31.4m), representing an
operating margin of 11.8% (4.5%).
- Net profit amounted to €78.2m (€8.5m), which represents a net
profit margin of 7.8% (1.2%).
- EBITDA was €195.3m (€104.4m), an increase by 87.0%. EBITDA
margin was 19.5% (14.9%).
- EBITDAaL amounted to €153.9m (€67.3m), corresponding to an
EBITDAaL margin of 15.4% (9.6%).
- Net cash flow from operating activities was €162.8m
(€116.1m).
- Basic/diluted earnings per share were €0.501
(€0.054).
REVENUE AND EARNINGS
|
€ millions
(€m)
|
Q3
2021
|
Q3
2020
|
Growth
|
9M
2021
|
9M
2020
|
Growth
|
FY
2020
|
|
Revenue
|
335.0
|
262.5
|
28%
|
1,001.1
|
700.1
|
43%
|
997.8
|
|
Operating profit
(EBIT)
|
30.0
|
27.3
|
10%
|
117.8
|
31.4
|
275%
|
61.3
|
|
Operating profit
margin
|
9.0%
|
10.4%
|
|
11.8%
|
4.5%
|
|
6.1%
|
|
Net profit
|
18.4
|
19.5
|
-6%
|
78.2
|
8.5
|
819%
|
27.3
|
|
Net profit
margin
|
5.5%
|
7.5%
|
|
7.8%
|
1.2%
|
|
2.7%
|
|
Basic/diluted
earnings per share, €
|
0.123
|
0.108
|
14%
|
0.501
|
0.054
|
828%
|
0.182
|
|
|
|
|
|
|
|
|
|
EBITDA
|
58.0
|
50.1
|
16%
|
195.3
|
104.4
|
87%
|
157.5
|
|
EBITDA
margin
|
17.3%
|
19.1%
|
|
19.5%
|
14.9%
|
|
15.8%
|
|
EBITDAaL
|
42.8
|
38.1
|
12%
|
153.9
|
67.3
|
129%
|
108.5
|
|
EBITDAaL
margin
|
12.8%
|
14.5%
|
|
15.4%
|
9.6%
|
|
10.9%
|
|
EBITA
|
32.6
|
30.1
|
8%
|
125.3
|
44.2
|
183%
|
76.9
|
|
EBITA
margin
|
9.7%
|
11.5%
|
|
12.5%
|
6.3%
|
|
7.7%
|
Definition and reconciliation of alternative performance
measures are available at
www.medicover.com/financial-information.
This is information that Medicover AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication through the agency of the contact person
set out below at 7.45 (CET) on 3 November
2021. This interim report and other information about
Medicover is available at medicover.com.
For further information, please contact:
Hanna Bjellquist, Head of
Investor Relations
Phone: +46 70 303 32 72
E-mail: hanna.bjellquist@medicover.com
Conference call: A conference call for analysts and
investors will be held today at 09.30 CET. To listen in please
register here. To ask questions please dial in and use code:
8236179
SE: 08-566 184 67
DE: +49 (0) 305 200 2085
UK: +44 (0) 2071 928 338
US: +1 646 741 3167
Financial Calendar
Year-end report January-December 2021
11 February 2022
Interim report January-March
27 April 2022
Annual general meeting
27 April 2022
Interim report April-June 22 July 2022
Interim report July-September
3 November 2022
Medicover is a leading international healthcare and diagnostic
services company and was founded in 1995. Medicover operates a
large number of ambulatory clinics, hospitals, specialty-care
facilities,laboratories and blood-drawing points and the
largest markets are Poland and
Germany. In 2020, Medicover had
revenue of EUR 998 million and more
than 32,000 employees. For more information, go to
www.medicover.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medicover/r/interim-report-july-september-2021,c3445833
The following files are available for download:
|
https://mb.cision.com/Main/15662/3445833/1490491.pdf
|
Interim report
July-September 2021
|